Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
Corbus Pharmaceuticals (NASDAQ: CRBP) has reported Q2 2025 financial results and provided updates on its three clinical programs. The company posted a net loss of $17.7 million ($1.44 per share) and holds $116.6 million in cash, sufficient to fund operations through Q2 2027.
Key developments include: CRB-701 (Nectin-4 targeting ADC) Phase 1/2 dose expansion data to be presented at ESMO 2025, with Fast Track designation for cervical cancer treatment; CRB-913 (obesity drug) has initiated its 7-day MAD study phase with SAD/MAD data expected later this year; and CRB-601 (anti-αvβ8 integrin mAB) is progressing with dose escalation data expected in Q4 2025.
All three clinical programs are on track for data readouts in H2 2025.Corbus Pharmaceuticals (NASDAQ: CRBP) ha comunicato i risultati finanziari del secondo trimestre 2025 e fornito aggiornamenti sui suoi tre programmi clinici. L'azienda ha riportato una perdita netta di 17,7 milioni di dollari (1,44 dollari per azione) e dispone di 116,6 milioni di dollari in liquidità, sufficienti a finanziare le operazioni fino al secondo trimestre 2027.
Gli sviluppi principali includono: dati di espansione della dose di fase 1/2 per CRB-701 (ADC mirato a Nectin-4) che saranno presentati all'ESMO 2025, con designazione Fast Track per il trattamento del cancro cervicale; CRB-913 (farmaco per l'obesità) ha avviato la fase di studio MAD di 7 giorni, con dati SAD/MAD attesi entro la fine dell'anno; e CRB-601 (anticorpo monoclonale anti-αvβ8 integrina) sta progredendo con dati di escalation della dose previsti per il quarto trimestre 2025.
Tutti e tre i programmi clinici sono in linea per le letture dei dati nella seconda metà del 2025.
Corbus Pharmaceuticals (NASDAQ: CRBP) ha informado los resultados financieros del segundo trimestre de 2025 y proporcionado actualizaciones sobre sus tres programas clínicos. La compañía registró una pérdida neta de 17,7 millones de dólares (1,44 dólares por acción) y cuenta con 116,6 millones de dólares en efectivo, suficientes para financiar sus operaciones hasta el segundo trimestre de 2027.
Los desarrollos clave incluyen: datos de expansión de dosis de fase 1/2 para CRB-701 (ADC dirigido a Nectin-4) que se presentarán en ESMO 2025, con designación Fast Track para el tratamiento del cáncer de cuello uterino; CRB-913 (medicamento para la obesidad) ha iniciado su fase de estudio MAD de 7 días, con datos SAD/MAD esperados para finales de este año; y CRB-601 (anticuerpo monoclonal anti-integrina αvβ8) avanza con datos de escalada de dosis esperados en el cuarto trimestre de 2025.
Los tres programas clínicos están en camino para la presentación de datos en la segunda mitad de 2025.
Corbus Pharmaceuticals (NASDAQ: CRBP)는 2025년 2분기 재무 결과를 발표하고 세 가지 임상 프로그램에 대한 최신 정보를 제공했습니다. 회사는 1,770만 달러의 순손실 (주당 1.44달러)을 기록했으며, 1억 1,660만 달러의 현금을 보유하고 있어 2027년 2분기까지 운영 자금을 충분히 확보하고 있습니다.
주요 개발 사항으로는: CRB-701 (Nectin-4 표적 ADC)의 1/2상 용량 확장 데이터가 2025년 ESMO에서 발표될 예정이며, 자궁경부암 치료를 위한 패스트 트랙 지정을 받았습니다; CRB-913 (비만 치료제)은 7일간의 다회 투여(MAD) 연구 단계를 시작했으며, 단회 및 다회 투여(SAD/MAD) 데이터가 올해 말에 공개될 예정입니다; 그리고 CRB-601 (항-αvβ8 인테그린 단클론 항체)은 용량 증량 데이터가 2025년 4분기에 발표될 예정입니다.
세 가지 임상 프로그램 모두 2025년 하반기에 데이터 발표가 예정되어 있습니다.
Corbus Pharmaceuticals (NASDAQ : CRBP) a publié ses résultats financiers du deuxième trimestre 2025 et a fourni des mises à jour sur ses trois programmes cliniques. La société a enregistré une perte nette de 17,7 millions de dollars (1,44 dollar par action) et dispose de 116,6 millions de dollars en liquidités, suffisants pour financer ses opérations jusqu'au deuxième trimestre 2027.
Les développements clés incluent : des données d'expansion de dose de phase 1/2 pour CRB-701 (ADC ciblant Nectin-4) qui seront présentées à l'ESMO 2025, avec une désignation Fast Track pour le traitement du cancer du col de l'utérus ; CRB-913 (médicament contre l'obésité) a lancé sa phase d'étude MAD de 7 jours, avec des données SAD/MAD attendues plus tard cette année ; et CRB-601 (anticorps monoclonal anti-intégrine αvβ8) progresse avec des données d'escalade de dose attendues au quatrième trimestre 2025.
Les trois programmes cliniques sont en bonne voie pour les lectures de données au second semestre 2025.
Corbus Pharmaceuticals (NASDAQ: CRBP) hat die Finanzergebnisse für das zweite Quartal 2025 veröffentlicht und Updates zu seinen drei klinischen Programmen gegeben. Das Unternehmen meldete einen Nettoverlust von 17,7 Millionen US-Dollar (1,44 US-Dollar je Aktie) und verfügt über 116,6 Millionen US-Dollar an liquiden Mitteln, ausreichend zur Finanzierung der Geschäftstätigkeit bis zum zweiten Quartal 2027.
Wesentliche Entwicklungen umfassen: Phase-1/2-Dosis-Erweiterungsdaten für CRB-701 (Nectin-4-gerichteter ADC), die auf der ESMO 2025 vorgestellt werden, mit Fast-Track-Status für die Behandlung von Gebärmutterhalskrebs; CRB-913 (Medikament gegen Fettleibigkeit) hat die 7-tägige MAD-Studienphase gestartet, mit SAD/MAD-Daten, die später in diesem Jahr erwartet werden; und CRB-601 (anti-αvβ8 Integrin mAB) macht Fortschritte, Dosissteigerungsdaten werden im vierten Quartal 2025 erwartet.
Alle drei klinischen Programme liegen im Zeitplan für Datenveröffentlichungen in der zweiten Hälfte des Jahres 2025.
- Strong cash position of $116.6M funding operations through Q2 2027
- FDA Fast Track designation granted for CRB-701 in cervical cancer treatment
- CRB-913 shows promising safety profile with no neuropsychiatric events in SAD portion
- All three clinical programs progressing on schedule with H2 2025 data readouts
- Net loss increased to $17.7M in Q2 2025 from $10.0M in Q2 2024
- Operating expenses increased by $8.2M to $19.2M year-over-year
Insights
Corbus advances three clinical programs with upcoming data readouts; maintains strong cash position through Q2 2027.
Corbus Pharmaceuticals is entering a potentially transformative period with data readouts expected across all three clinical programs in H2 2025. The company's lead asset CRB-701, a next-generation Nectin-4 targeting ADC for solid tumors, continues to show promising enrollment rates and will present Phase 1/2 dose expansion data at ESMO in October from over 100 participants with HNSCC, cervical, and urothelial cancers. The FDA's Fast Track designation for CRB-701 in relapsed/refractory metastatic cervical cancer further validates this program's potential.
Their obesity program CRB-913 has successfully advanced to the 7-day multiple ascending dose (MAD) portion of its Phase 1 study, with no treatment-related neuropsychiatric events reported in the SAD portion - a critical safety milestone for CB1 inverse agonists, which historically faced CNS-related safety issues. The company reports CRB-913 is 50 times more peripherally restricted than rimonabant and 15 times more than monlunabant, potentially offering improved safety.
The third program, CRB-601, an anti-αvβ8 integrin monoclonal antibody targeting TGFβ activation in the tumor microenvironment, continues dose escalation with data expected in Q4 2025.
Financially, Corbus reported a net loss of
- Phase 1/2 dose expansion data for Nectin-4 targeting ADC CRB-701 to be presented at ESMO 2025
- Initiated 7-day MAD portion of Phase 1 study for obesity drug CRB-913
- All three clinical programs (CRB-701, CRB-913, CRB-601) on track for data readouts in the second half of 2025
NORWOOD, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage oncology and obesity company, today provided a corporate update and reported financial results for the quarter ended June 30, 2025.
“The second half of 2025 is shaping up to be impactful, with scheduled data readouts anticipated for all three of our clinical programs,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. “We have been very pleased with the strong rate of enrollment in the CRB-701 study and look forward to presenting the Phase 1/2 dose expansion data at ESMO in October, which will include data from over 100 participants from the U.S. and Europe with HNSCC, cervical and mUC tumors. For our obesity drug CRB-913, we expect to present SAD/MAD data later this year and to initiate a Phase 1b dose-range finding study in the fourth quarter of 2025.”
Key Corporate and Program Updates
CRB-701 for the treatment of solid tumors, is a next-generation antibody drug conjugate (ADC) targeting Nectin-4 that contains a site-specific, cleavable linker and a precise drug antibody ratio (DAR) of 2 using monomethyl auristatin E (MMAE) as the payload.
- Dose optimization in the Phase 1/2 study is on-going with dosing at 2.7 mg/kg and 3.6 mg/kg in participants with head and neck squamous cell carcinoma (HNSCC), cervical and urothelial (mUC) tumors. In June 2025, the first participant in the combination arm of the study was dosed with pembrolizumab.
- Phase 1/2 dose expansion data will be presented for the first time as a poster (#967P) at the European Society for Medical Oncology (ESMO) Congress on October 19, 2025 from 12:00-12:45 CEST.
- The Company expects to complete dose optimization and identify the recommended Phase 2 dose (RP2D) in the fourth quarter of 2025.
- The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CRB-701 for the treatment of relapsed or refractory metastatic cervical cancer.
CRB-913 is a second generation, highly peripherally restricted, oral small molecule CB1 receptor inverse agonist drug designed for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss but the previous class of such experimental drugs was abandoned due to potential neuropsychiatric adverse event risks. CRB-913 is a member of a new class of peripherally restricted CB1 inverse agonists designed to have reduced brain penetration.
- The Company initiated the multiple ascending dose (MAD) portion of the Phase 1 trial in June 2025. This follows safety and pharmacokinetics (PK) data analysis of the single ascending dose (SAD) portion of the study launched in March 2025. No treatment-related neuropsychiatric events have been seen to date in the SAD portion of the study. The MAD portion of the study is scheduled for completion in the third quarter, and the Company expects to report SAD/MAD data later this year. The initiation of Phase 1b dose-range finding study in obese non-diabetic individuals is on track for Q4 2025.
- The Company’s pre-clinical data demonstrates CRB-913 is markedly more peripherally restricted than either monlunabant or rimonabant. CRB-913 has a brain to plasma ratio 50-times lower than rimonabant and is 15-times more peripherally restricted than monlunabant.
CRB-601 is a potent and selective anti-αvβ8 integrin monoclonal antibody (mAB) designed to block the activation of latent TGFβ in the tumor micro-environment to treat solid tumors.
- The first participant was dosed in December 2024 in the dose escalation monotherapy portion of a Phase 1 study which is being conducted in the U.S. and Europe. The Company is on track to report dose escalation data in Q4 2025.
Financial Results for the Quarter Ended June 30, 2025
The Company reported a net loss of approximately
Operating expenses increased by
As of June 30, 2025, the Company had
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a clinical stage oncology and obesity company and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.
INVESTOR CONTACT:
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com
Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com
---tables to follow---
| Corbus Pharmaceuticals Holdings, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share amounts) (Unaudited) | ||||||||||||||||
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | 15,187 | $ | 6,865 | $ | 30,829 | $ | 12,627 | ||||||||
| General and administrative | 3,965 | 4,123 | 8,098 | 7,984 | ||||||||||||
| Total operating expenses | 19,152 | 10,988 | 38,927 | 20,611 | ||||||||||||
| Operating loss | (19,152 | ) | (10,988 | ) | (38,927 | ) | (20,611 | ) | ||||||||
| Other income (expense), net: | ||||||||||||||||
| Interest and investment income, net | 1,314 | 1,600 | 2,995 | 2,628 | ||||||||||||
| Interest expense | — | (652 | ) | — | (1,491 | ) | ||||||||||
| Other income, net | 176 | 43 | 1,292 | 2,578 | ||||||||||||
| Total other income, net | 1,490 | 991 | 4,287 | 3,715 | ||||||||||||
| Net loss | $ | (17,662 | ) | $ | (9,997 | ) | $ | (34,640 | ) | $ | (16,896 | ) | ||||
| Net loss per share, basic and diluted | $ | (1.44 | ) | $ | (0.90 | ) | $ | (2.83 | ) | $ | (1.75 | ) | ||||
| Weighted average number of common shares outstanding, basic and diluted | 12,240,443 | 11,053,241 | 12,221,373 | 9,681,875 | ||||||||||||
| Comprehensive loss: | ||||||||||||||||
| Net loss | $ | (17,662 | ) | $ | (9,997 | ) | $ | (34,640 | ) | $ | (16,896 | ) | ||||
| Other comprehensive loss: | ||||||||||||||||
| Change in unrealized loss on marketable debt securities | (16 | ) | (59 | ) | (74 | ) | (387 | ) | ||||||||
| Total other comprehensive loss | (16 | ) | (59 | ) | (74 | ) | (387 | ) | ||||||||
| Total comprehensive loss | $ | (17,678 | ) | $ | (10,056 | ) | $ | (34,714 | ) | $ | (17,283 | ) | ||||
| Corbus Pharmaceuticals Holdings, Inc. Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts) | ||||||||
| June 30, 2025 (unaudited) | December 31, 2024 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 20,044 | $ | 17,198 | ||||
| Investments | 96,548 | 131,864 | ||||||
| Restricted cash | 285 | 285 | ||||||
| Prepaid expenses and other current assets | 5,948 | 3,629 | ||||||
| Total current assets | 122,825 | 152,976 | ||||||
| Restricted cash | 385 | 385 | ||||||
| Property and equipment, net | 251 | 385 | ||||||
| Operating lease right-of-use assets | 1,624 | 2,133 | ||||||
| Total assets | $ | 125,085 | $ | 155,879 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 3,988 | $ | 4,786 | ||||
| Accrued expenses | 7,650 | 5,426 | ||||||
| Operating lease liabilities, current | 1,695 | 1,606 | ||||||
| Total current liabilities | 13,333 | 11,818 | ||||||
| Operating lease liabilities, noncurrent | 761 | 1,633 | ||||||
| Total liabilities | 14,094 | 13,451 | ||||||
| Stockholders’ equity | ||||||||
| Preferred stock, | — | — | ||||||
| Common stock, 12,254,069 and 12,179,482 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively | 1 | 1 | ||||||
| Additional paid-in capital | 622,562 | 619,285 | ||||||
| Accumulated deficit | (511,533 | ) | (476,893 | ) | ||||
| Accumulated other comprehensive (loss) gain | (39 | ) | 35 | |||||
| Total stockholders’ equity | 110,991 | 142,428 | ||||||
| Total liabilities and stockholders’ equity | $ | 125,085 | $ | 155,879 | ||||
FAQ
What are the key financial metrics for Corbus Pharmaceuticals (CRBP) in Q2 2025?
What is the status of CRB-701 clinical trials at Corbus?
How is Corbus's obesity drug CRB-913 progressing in clinical trials?
How long can Corbus Pharmaceuticals fund its operations with current cash?
What are the upcoming catalysts for CRBP stock in 2025?
